Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
Endo International plc says it still believes that its Vasostrict (vasopressin) brand will be a significant contributor for the company this year despite the onset of generic competition.
Eagle recently launched the first US generic rival to Vasostrict with 180 days of market exclusivity. American Regent has also received approval for its 505(b)(2) hybrid new drug application product
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”
